Drugs / Autologous Dendritic Cell (DC) Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06522919 | Jan 2025 → Apr 2026 overdue | colorectal carcinoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Dendritic Cell (DC) Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06522919 ↗ |
| Modality | Vaccine | “Dendritic cell (DC) vaccines, though historically limited in effectiveness, show potential when combined with ICIs.” PMID 41275134 ↗ Nov 2025 |